On Nov. 20, 2012, the FDA released its own version of the Form 483 it had issued to the St. Jude facility in question. The FDA’s version revealed that a majority of the observed problems directly affected the Durata lead. After this information was released, St. Jude stock, which has 301 million shares outstanding, fell by $4.34, a 12 percent drop.During the class period, St. Jude CEO Daniel Starks, privy to non-public information concerning the company and the FDA report on its Durata product, sold 200,000 shares of company stock.
Hagens Berman Investigates St. Jude Medical, Inc., Advises Investors Of Oct. 17 To Nov. 20, 2012 Class Period In Lawsuit
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts